BRIEF-Celldex Therapeutics Says Barzolvolimab Meets Primary Efficacy Endpoint In Phase 2 CSU Study

Celldex Therapeutics, Inc.

Celldex Therapeutics, Inc.

CLDX

0.00

June 14 (Reuters) - Celldex Therapeutics Inc CLDX.O:

  • CELLDEX PRESENTS LONG-TERM BARZOLVOLIMAB RESULTS DEMONSTRATING SUSTAINED OFF-TREATMENT IMPROVEMENT IN ANGIOEDEMA IN PATIENTS WITH CSU AT THE EUROPEAN ACADEMY OF ALLERGY AND CLINICAL IMMUNOLOGY ANNUAL MEETING

  • CELLDEX THERAPEUTICS - BARZOLVOLIMAB MEETS PRIMARY EFFICACY ENDPOINT IN PHASE 2 CSU STUDY

Source text: ID:nGNXc8lPHs

Further company coverage: CLDX.O


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.